Company Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.
The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.
Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr.
Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.
The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016.
The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
| Country | United States |
| IPO Date | Aug 8, 1995 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Craig E. Fraser |
Contact Details
Address: 2600 Kelly Road, Suite 100 Warrington, Pennsylvania 18976 United States | |
| Phone | (215) 488-9300 |
| Website | windtreetx.com |
Stock Details
| Ticker Symbol | WINT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000946486 |
| CUSIP Number | 97382D303 |
| ISIN Number | US97382D4025 |
| Employer ID | 94-3171943 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig E. Fraser | Chairman, President, Chief Executive Officer and Interim Principal Officer |
| Dr. Steven G. Simonson | Senior Vice President and Chief Medical Officer |
| Eric L. Curtis M.B.A. | Senior Vice President and Chief Operating Officer |
| Jamie McAndrew | Vice President, Controller, Chief Accounting Officer and Corporate Secretary |
| George Cox | Vice President of Technical Operations |
| Dr. Pratap Paruchuru | Executive Director of Clinical Development |
| Tracy Rarick | Head of Operations and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 17, 2024 | 8-K | Current Report |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 10, 2024 | 8-K | Current Report |
| Apr 8, 2024 | 8-K | Current Report |
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 12, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |